Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.3
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Product Information [Line Items]        
Total net revenue $ 1,446,066 $ 2,350,386 $ 4,569,146 $ 7,154,429
General corporate activities 3,738,912 4,324,250 12,004,691 13,161,321
Total operating expenses (3,738,912) (4,324,250) (12,004,691) (13,161,321)
Total operating loss (2,292,846) (1,973,864) (7,435,545) (6,006,892)
Non-operating (expense), net (2,755,056) (24,417) (4,295,882) (54,392)
Net loss before income tax expense (5,047,902) (1,998,281) (11,731,427) (6,061,284)
Income tax expense (3,182) (2,559) (40,861) (11,650)
Net loss (5,051,084) (2,000,840) (11,772,288) (6,072,934)
Diagnostic R&D [Member]        
Product Information [Line Items]        
Total net revenue 1,731 8,654
General corporate activities (473,900) (368,202) (1,420,290) (1,264,696)
Total operating expenses 473,900 368,202 1,420,290 1,264,696
Laboratory Services [Member]        
Product Information [Line Items]        
Total net revenue 1,446,066 2,348,655 4,569,146 7,145,775
General corporate activities (1,509,795) (2,150,825) (5,423,922) (7,423,109)
Total operating expenses 1,509,795 2,150,825 5,423,922 7,423,109
General Corporate Activities [Member]        
Product Information [Line Items]        
General corporate activities (1,755,217) (1,805,223) (5,160,479) (4,473,516)
Total operating expenses $ 1,755,217 $ 1,805,223 $ 5,160,479 $ 4,473,516